JHE-CYUAN GUOTa-Chen HuangCHIA-CHI LINMIN-SHU HSIEHChang C.-H.PEI-MING HUANGJANG-MING LEEFeng-Ming HsuCHIA-HSIEN CHENGHSIU-PO WANGKUN-HUEI YEHANN-LII CHENGCHIH-HUNG HSU2020-03-052020-03-0520151556-0864https://www.scopus.com/inward/record.uri?eid=2-s2.0-84942508462&doi=10.1097%2fJTO.0000000000000651&partnerID=40&md5=32869c6c850026803933bef54e0ade0fhttps://scholars.lib.ntu.edu.tw/handle/123456789/470790Introduction: To determine whether the postchemoradiotherapy (post-CRT) pathologic stage predicts the outcomes of patients with locally advanced esophageal squamous cell carcinoma (ESCC) undergoing preoperative CRT followed by surgery. Methods: From three phase II trials of preoperative CRT for locally advanced ESCC, 140 patients were included. Preoperative CRT comprised twice weekly paclitaxel and cisplatin-based regimens and 40-Gy radiotherapy in 20 fractions. The post-CRT pathologic stage was classified according to the American Joint Committee on Cancer, 7th edition staging system. The prognostic effects of clinicopathologic factors were analyzed using Cox regression. Results: With a median follow-up of 61.9 months, the median progression-free survival (PFS) and overall survival (OS) of the entire cohort were 24.5 and 30.9 months, respectively. The post-CRT pathologic stage was 0 in 34.5%, I in 12.9%, II in 29.3%, III in 13.6%, and ypT0N1-2 in 6.4% of the patients. The median PFS was 47.2, 25.9, 16.0, 9.4, and 15.1 months, and the median OS was 57.4, 34.1, 26.2, 14.1, and 17.6 months for patients with post-CRT pathologic stage 0, I, II, III, and ypT0N1-2, respectively. In multivariate analysis, performance status (p < 0.001), tumor location (p = 0.016), and extranodal extension (p = 0.024) were independent prognostic factors for PFS, whereas performance status (p < 0.001) and post-CRT pathologic stage (p = 0.027) were independent prognostic factors for OS. Conclusions: The post-CRT pathologic stage classified by American Joint Committee on Cancer, 7th edition staging system predicted the survival of locally advanced ESCC patients who underwent preoperative paclitaxel and cisplatin-based CRT followed by esophagectomy. ? 2015 by the International Association for the Study of Lung Cancer.[SDGs]SDG3cetuximab; cisplatin; fluorouracil; folinic acid; paclitaxel; adjuvant chemoradiotherapy; adult; advanced cancer; aged; Article; cancer patient; cancer prognosis; cancer radiotherapy; cancer staging; cancer surgery; cancer survival; drug megadose; endoscopic echography; esophageal squamous cell carcinoma; esophagogastroduodenoscopy; esophagus resection; female; follow up; human; major clinical study; male; middle aged; multimodality cancer therapy; outcome assessment; overall survival; phase 2 clinical trial; positron emission tomography; priority journal; progression free survival; surgical patient; treatment duration; cancer staging; Carcinoma, Squamous Cell; chemoradiotherapy; Esophageal Neoplasms; pathology; prognosis; United States; world health organization; Adult; Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Female; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; United States; World Health Organizationjournal article10.1097/JTO.0000000000000651263136832-s2.0-84942508462